{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Underwood J"],"funding":["National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["787-790"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6376853"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(3)"],"pubmed_abstract":["<h4>Background</h4>Drug-related adverse events (AEs) are reported to be common amongst patients receiving outpatient parenteral antimicrobial therapy (OPAT). However, comparative data regarding intravenous (iv) catheter-related AEs are lacking.<h4>Objectives</h4>To compare drug- and iv catheter-related AEs from a large UK OPAT centre.<h4>Patients and methods</h4>We reviewed 544 OPAT episodes [median (IQR) age: 57 (39-71) years, 60% male, 13% with diabetes] with a median (IQR) duration of 7 (2-18) days. Clinically significant drug- and iv catheter-related AEs were calculated as a percentage of OPAT episodes with an AE and also as AEs per 1000 iv drug/catheter days.<h4>Results</h4>Drug-related AEs complicated 13 (2.4%) OPAT episodes at 1.7 (95% CI 0.9-2.9) per 1000 drug days. Catheter-relate"],"journal":["The Journal of antimicrobial chemotherapy"],"pubmed_title":["Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy."],"pmcid":["PMC6376853"],"funding_grant_id":["CL-2016-20-001","WT102807","CL-2016-18-011","WT101766"],"pubmed_authors":["Pollara G","Collins S","Underwood J","Logan S","Marks M"],"additional_accession":[]},"is_claimable":false,"name":"Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy.","description":"<h4>Background</h4>Drug-related adverse events (AEs) are reported to be common amongst patients receiving outpatient parenteral antimicrobial therapy (OPAT). However, comparative data regarding intravenous (iv) catheter-related AEs are lacking.<h4>Objectives</h4>To compare drug- and iv catheter-related AEs from a large UK OPAT centre.<h4>Patients and methods</h4>We reviewed 544 OPAT episodes [median (IQR) age: 57 (39-71) years, 60% male, 13% with diabetes] with a median (IQR) duration of 7 (2-18) days. Clinically significant drug- and iv catheter-related AEs were calculated as a percentage of OPAT episodes with an AE and also as AEs per 1000 iv drug/catheter days.<h4>Results</h4>Drug-related AEs complicated 13 (2.4%) OPAT episodes at 1.7 (95% CI 0.9-2.9) per 1000 drug days. Catheter-relate","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-07-09T13:22:11.197Z","creation":"2019-08-04T07:32:15Z"},"accession":"S-EPMC6376853","cross_references":{"pubmed":["30462237"],"doi":["10.1093/jac/dky474"]}}